Work

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Year: 2019

Type: review

Abstract: Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges.

Source: Pharmacology & Therapeutics

DOI: 10.1016/j.pharmthera.2019.04.006

Authors: Frans V. Suurs, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries, Derk Jan A. de Groot

Institutions: University Medical Center Groningen, University of Groningen

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,900